IRON Financial LLC raised its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 86.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 10,578 shares of the company's stock after buying an additional 4,893 shares during the quarter. Johnson & Johnson accounts for about 1.0% of IRON Financial LLC's holdings, making the stock its 23rd biggest position. IRON Financial LLC's holdings in Johnson & Johnson were worth $1,754,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Sollinda Capital Management LLC acquired a new position in Johnson & Johnson in the 1st quarter worth about $276,000. Monument Capital Management grew its stake in shares of Johnson & Johnson by 96.2% in the 1st quarter. Monument Capital Management now owns 4,165 shares of the company's stock valued at $691,000 after buying an additional 2,042 shares in the last quarter. Amalgamated Bank increased its holdings in Johnson & Johnson by 1.0% in the first quarter. Amalgamated Bank now owns 478,214 shares of the company's stock worth $79,307,000 after buying an additional 4,675 shares during the last quarter. Verity Asset Management Inc. raised its position in Johnson & Johnson by 99.4% during the first quarter. Verity Asset Management Inc. now owns 10,698 shares of the company's stock valued at $1,774,000 after acquiring an additional 5,334 shares in the last quarter. Finally, Crown Wealth Group LLC bought a new stake in Johnson & Johnson in the first quarter worth approximately $242,000. Hedge funds and other institutional investors own 69.55% of the company's stock.
Johnson & Johnson Stock Performance
JNJ stock traded up $0.60 on Thursday, reaching $156.16. 1,446,381 shares of the company were exchanged, compared to its average volume of 8,020,342. The firm has a market capitalization of $375.74 billion, a PE ratio of 17.37, a PEG ratio of 2.36 and a beta of 0.41. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The stock's fifty day moving average price is $153.63 and its 200 day moving average price is $153.88. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The company had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. On average, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.33%. The ex-dividend date of this dividend was Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is presently 57.84%.
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on JNJ shares. Barclays cut their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Morgan Stanley raised their target price on Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Wednesday, April 16th. Wall Street Zen upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 21st. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.
Check Out Our Latest Report on Johnson & Johnson
Johnson & Johnson Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Stories
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
